TG TherapeuticsTGTX
TGTX
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
118% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 44
52% more call options, than puts
Call options by funds: $70.9M | Put options by funds: $46.8M
40% more capital invested
Capital invested by funds: $1.7B [Q2] → $2.38B (+$680M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 72
19% more funds holding
Funds holding: 254 [Q2] → 302 (+48) [Q3]
4.09% more ownership
Funds ownership: 61.63% [Q2] → 65.73% (+4.09%) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
26%
downside
Avg. target
$43
43%
upside
High target
$55
85%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
JP Morgan Eric Joseph 45% 1-year accuracy 13 / 29 met price target | 45%upside $43 | Overweight Maintained | 25 Nov 2024 |
HC Wainwright & Co. Edward White 28% 1-year accuracy 41 / 144 met price target | 85%upside $55 | Buy Maintained | 5 Nov 2024 |
Goldman Sachs Corinne Jenkins 30% 1-year accuracy 3 / 10 met price target | 26%downside $22 | Neutral Maintained | 5 Nov 2024 |
TD Cowen Tara Bancroft 50% 1-year accuracy 2 / 4 met price target | 68%upside $50 | Buy Initiated | 29 Oct 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 day ago
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
TG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to report initial data on the subcutaneous form of Briumvi in early 2025, which could be positive given the company's upbeat statements on its prospects. While the company has approved a $100M share buyback, it only bought back $2.1M in Q3'24. Further buybacks could limit downside in the stock.
Neutral
GlobeNewsWire
5 days ago
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd Annual J.P.
Negative
Market Watch
1 month ago
20 stocks likely to lag the S&P 500 over the next year — for this one reason
Difficult-to-short stocks often trade at artificially inflated, unsustainable prices.
Positive
Investors Business Daily
1 month ago
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Neutral
GlobeNewsWire
1 month ago
TG Therapeutics to Participate in the Evercore HealthCONx Conference
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
Neutral
GlobeNewsWire
1 month ago
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year.
Positive
Investors Business Daily
2 months ago
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Positive
Seeking Alpha
2 months ago
TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial.
Negative
Seeking Alpha
2 months ago
TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell
TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal antibody for multiple sclerosis, generated $83.3 million in Q3, showing a 15% QoQ growth but a deceleration in revenue growth. The Company raised its full-year revenue guidance to $300-305 million, indicating confidence in Briumvi's market performance despite competitive pressures from Ocrevus and Kesimpta.
Neutral
Seeking Alpha
2 months ago
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Tara Bancroft - TD Cowen Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B.
Charts implemented using Lightweight Charts™